在实验室中对SLCO2B1遗传变异的鉴定
Alli Sinokki1, Annika Miinalainen1, Saara Kivioja1
1Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland.
Journal of pharmaceutical sciences
|March 28, 2025
概括
在OATP2B1载体 (编码SLCO2B1) 的遗传变异可以影响药物代谢. 罕见的变异c.1559G>C显著损害OATP2B1功能,影响药物处置.
科学领域:
- 药物基因组学 药物基因组学
- 药物运输器功能 药物运输器功能
背景情况:
- OATP2B1 (编码为SLCO2B1) 是肠道和肝脏中的关键药物载体.
- 在SLCO2B1中的遗传变异可以改变OATP2B1基质药物的处置.
- 罕见的OATP2B1变异的功能影响尚不清楚.
研究的目的:
- 描述自然存在的SLCO2B1.1.的单核酸变异的体外功能.
- 评估特定的SLCO2B1变体 (c.601G>A,c.935G>A,c.953C>T,c.1175C>,c.1457C>T,c.1559G>C,c.1596C>A和c.601G>A + c.935G>A单体型) 对OATP2B1载体活性的影响.
主要方法:
- 使用了表达OATP2B1参考和变体形式的HEK293细胞.
- 测量了OATP2B1基质的细胞吸收 (二甲素,5-碳氧素素,硫酸,罗斯瓦斯塔丁).
- 使用基于LC-MS/MS的定量向绝对蛋白质量学来量化OATP2B1变异蛋白质的丰度.
主要成果:
- SLCO2B1变异c.1559G>C几乎完全影响了所有测试基质的OATP2B1介导吸收.
- c.1559G>C变体的蛋白质丰度有所降低,但与功能丧失不成比例.
- 其他研究的SLCO2B1变体的蛋白质丰度和运输功能相似或略有减少.
结论:
- c.1559G>C变体代表了OATP2B1.1.的显著功能丧失变体.
- 这些发现有助于解释涉及SLCO2B1变体的临床药物遗传研究.
- 1559G>C等罕见变异的特征对于预测药物反应和潜在的不良事件至关重要.
相关概念视频
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


